Avanos Medical, Inc. (AVNS)
USD 16.18
(-4.94%)
USD 16.18
(-4.94%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -61.8 Million USD | -222.38% |
| 2022 | 50.5 Million USD | 701.59% |
| 2021 | 6.3 Million USD | 123.16% |
| 2020 | -27.2 Million USD | 40.74% |
| 2019 | -45.9 Million USD | -179.83% |
| 2018 | 57.5 Million USD | -27.49% |
| 2017 | 79.3 Million USD | 99.25% |
| 2016 | 39.8 Million USD | 109.34% |
| 2015 | -426.3 Million USD | -1673.06% |
| 2014 | 27.1 Million USD | -82.47% |
| 2013 | 154.6 Million USD | 1.31% |
| 2012 | 152.6 Million USD | 7.16% |
| 2011 | 142.4 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 1.8 Million USD | 300.0% |
| 2024 Q3 | 4.3 Million USD | 138.89% |
| 2024 Q1 | -900 Thousand USD | -108.57% |
| 2023 Q3 | -3.7 Million USD | 94.57% |
| 2023 Q2 | -68.1 Million USD | -13520.0% |
| 2023 Q1 | -500 Thousand USD | -102.96% |
| 2023 FY | -61.8 Million USD | -222.38% |
| 2023 Q4 | 10.5 Million USD | 383.78% |
| 2022 FY | 50.5 Million USD | 701.59% |
| 2022 Q4 | 16.9 Million USD | 7.64% |
| 2022 Q3 | 15.7 Million USD | 37.72% |
| 2022 Q2 | 11.4 Million USD | 96.55% |
| 2022 Q1 | 5.8 Million USD | -42.0% |
| 2021 Q2 | 37.9 Million USD | 598.68% |
| 2021 Q4 | 10 Million USD | 128.49% |
| 2021 FY | 6.3 Million USD | 123.16% |
| 2021 Q3 | -35.1 Million USD | -192.61% |
| 2021 Q1 | -7.6 Million USD | 83.9% |
| 2020 Q2 | -3 Million USD | -181.08% |
| 2020 Q1 | 3.7 Million USD | 160.66% |
| 2020 Q3 | 19.3 Million USD | 743.33% |
| 2020 FY | -27.2 Million USD | 40.74% |
| 2020 Q4 | -47.2 Million USD | -344.56% |
| 2019 Q4 | -6.1 Million USD | 46.96% |
| 2019 Q2 | -8 Million USD | 60.59% |
| 2019 Q3 | -11.5 Million USD | -43.75% |
| 2019 Q1 | -20.3 Million USD | -822.73% |
| 2019 FY | -45.9 Million USD | -179.83% |
| 2018 FY | 57.5 Million USD | -27.49% |
| 2018 Q4 | -2.2 Million USD | -152.38% |
| 2018 Q3 | 4.2 Million USD | -88.1% |
| 2018 Q2 | 35.3 Million USD | 74.75% |
| 2018 Q1 | 20.2 Million USD | -38.41% |
| 2017 Q3 | 16.6 Million USD | -2.92% |
| 2017 FY | 79.3 Million USD | 99.25% |
| 2017 Q4 | 32.8 Million USD | 97.59% |
| 2017 Q2 | 17.1 Million USD | 33.59% |
| 2017 Q1 | 12.8 Million USD | 28.0% |
| 2016 Q3 | 9.1 Million USD | 40.0% |
| 2016 FY | 39.8 Million USD | 109.34% |
| 2016 Q4 | 10 Million USD | 9.89% |
| 2016 Q2 | 6.5 Million USD | -54.23% |
| 2016 Q1 | 14.2 Million USD | -2.07% |
| 2015 FY | -426.3 Million USD | -1673.06% |
| 2015 Q4 | 14.5 Million USD | 103.08% |
| 2015 Q3 | -470.5 Million USD | -5981.25% |
| 2015 Q2 | 8 Million USD | -63.13% |
| 2015 Q1 | 21.7 Million USD | 1004.17% |
| 2014 Q1 | 41.4 Million USD | 4.02% |
| 2014 FY | 27.1 Million USD | -82.47% |
| 2014 Q2 | -4.5 Million USD | -110.87% |
| 2014 Q4 | -2.4 Million USD | 67.57% |
| 2014 Q3 | -7.4 Million USD | -64.44% |
| 2013 Q2 | 38.6 Million USD | 36.4% |
| 2013 Q4 | 39.8 Million USD | -16.91% |
| 2013 Q1 | 28.3 Million USD | 0.0% |
| 2013 FY | 154.6 Million USD | 1.31% |
| 2013 Q3 | 47.9 Million USD | 24.09% |
| 2012 FY | 152.6 Million USD | 7.16% |
| 2011 FY | 142.4 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Abbott Laboratories | 5.72 Billion USD | 101.08% |
| Allurion Technologies Inc. | -82.3 Million USD | 24.913% |
| Artivion, Inc. | -30.69 Million USD | -101.369% |
| Butterfly Network, Inc. | -133.69 Million USD | 53.777% |
| Butterfly Network, Inc. | -133.69 Million USD | 53.777% |
| Bio-Rad Laboratories, Inc. | -637.32 Million USD | 90.303% |
| Boston Scientific Corporation | 1.59 Billion USD | 103.879% |
| Perspective Therapeutics, Inc. | -14.67 Million USD | -321.268% |
| CONMED Corporation | 64.45 Million USD | 195.875% |
| Edwards Lifesciences Corporation | 1.4 Billion USD | 104.407% |
| Paragon 28, Inc. | -47.84 Million USD | -29.178% |
| Glaukos Corporation | -134.66 Million USD | 54.107% |
| Globus Medical, Inc. | 122.87 Million USD | 150.296% |
| Inspire Medical Systems, Inc. | -21.15 Million USD | -192.157% |
| Integer Holdings Corporation | 90.65 Million USD | 168.174% |
| Medtronic plc | 3.67 Billion USD | 101.681% |
| Nevro Corp. | -92.21 Million USD | 32.981% |
| Owlet, Inc. | -32.9 Million USD | -87.836% |
| Penumbra, Inc. | 90.95 Million USD | 167.946% |
| Vicarious Surgical Inc. | -71.07 Million USD | 13.045% |
| Smith & Nephew plc | 263 Million USD | 123.498% |
| Sonendo, Inc. | -60.91 Million USD | -1.446% |
| STERIS plc | 378.23 Million USD | 116.339% |
| Stryker Corporation | 3.16 Billion USD | 101.953% |
| Vapotherm, Inc. | -58.19 Million USD | -6.198% |
| Zimmer Biomet Holdings, Inc. | 1.02 Billion USD | 106.035% |